Skip to content

Smoking Cessation for Fathers of Sick Children

mHealth-based Motivational Counselling Integrate With a Sample of Nicotine Replacement Therapy for Fathers of Sick Children Who Smoke Cigarettes: A Pilot Randomized Controlled Trial

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07014124
Acronym
Quit-for-Love
Enrollment
160
Registered
2025-06-10
Start date
2025-03-18
Completion date
2026-04-01
Last updated
2025-06-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cigarette Smoking, mHealth Intervention

Keywords

tobacco exposure, sick children, quit smoking, Nicotine replacement therapy, mHealth support, smoking fathers

Brief summary

The project aims to develop and examine the feasibility, acceptability, and preliminary effectiveness of a proactive intervention model combined brief advice, nicotine replacement therapy sampling and mHealth-based individual counselling in increasing smoking abstinence for fathers of sick children.

Detailed description

Targeted participants are fathers of sick children who smoke daily in the past 7 days and live together with their children. The primary caregiver will be selected if both parents smoke. Participants will be recruited from pediatric wards/outpatient departments of Queen Mary Hospital (QMH), a major acute hospital in Hong Kong. The recruitment will be extended to other public hospitals if needed. This study will be a two-arm, parallel pilot randomized trial with follow-ups at 1-, 3-, and 6-month since enrolment using standard methodology (CONSORT) to evaluate the effectiveness of the intervention. Surveys will be collected via telephone and children's saliva will be collected face-to-face at 3-months and 6-months after randomisation using Alere iScreen OFD saliva cotinine test device. Semi-structured individual telephone or face-to-face in-depth interviews will be conducted with the participants in the intervention group at 6 months follow-up to explore the participants' perception towards the intervention. This study's clinical outcome will be biochemically validated abstinence at 3 months after randomisation. Secondary outcomes include validated abstinence at 6 months after randomisation, self-reported 7-day point prevalence abstinence (PPA), 24-hour quit attempts, and smoking reduction by at least 50% at 3 and 6 months. Incentives of HK$200 will be given to participants who report 7-day PPA at 1 month post randomisation. Additionally, incentives of HK$ 500 will be provided for the completion of each biochemical validation (a total $1000 for validation at 3- and 6-month). Such an amount can increase the response rate in our experience. Another incentive of $200 will be given to subjects completing qualitative interviews.

Interventions

Participants will be advised to choose the NRT according to their preferences and daily cigarette consumption. Cigarette consumption of ≤20 daily will receive the 14mg patch or 2mg gum and participants consume \>20 cigarettes daily will receive the 21mg patch. An NRT use card (Appendix 6 draft) containing the instructions and potential side effects were given with a brief oral explanation. Full course of pharmacological treatment for 12-week are available in smoking cessation services. Participants requesting for additional or full course of NRT will be actively refer to the respective services as part of the Referral step in the AWARD model (Ask, Warn, Advise, Refer, and Do-it-again).

The mHealth intervention will be delivered via the most popular instant messaging app in Hong Kong (WhatsApp). A total of 24 messages with contents including the harms of smoking and smoke exposure for children, encouragement, benefits of quitting for children, methods of quitting, dealing with craving, and measures to reduce cigarette smoke exposure at home will be provided. The messages will be scheduled in a tapering schedule that participants will receive 5 messages in the first week, then cut down to 3 messages/week for the next 4 weeks and 1 message/week for the last 7 weeks. Using a more personalized approach, the messages will be tailored to the participants' motivation, intention to quit and other quitting patterns collected at baseline. Real-time conversations could be initiated by participants themselves, triggered by regular messages, or through prompt inquires (e.g., asking about the quitting progress).

BEHAVIORALBrief cessation advice and self-help material

At baseline, participants will receive brief face-to-face advice on quitting smoking for the health of the children using the validated AWARD model (Ask, Warn, Advise, Refer, Do-it-again) with a print-based self-help material providing detailed information on health hazards of SHS exposure on children, methods to deal with craving and withdrawal symptoms, and measures on preventing SHS exposure for children at home.

Sponsors

The University of Hong Kong
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

for parents: * Parents (mainly fathers) aged ≥18 years and smoke at least one cigarette (including alternative tobacco products) daily in the past seven days * Living with a child aged \<18 years who attended the clinic or were admitted to the pediatric ward * Hong Kong residents able to read and communicate in Cantonese or Putonghua * Owned a smartphone and can use an instant messaging app (e.g., WhatsApp, Facebook) Inclusion criteria for children * Children aged \<18 years who attended the clinic or were admitted to the pediatric ward * Lives with at least one or more parents who smoke at least one cigarette (including alternative tobacco products) daily in the past seven days * Able to provide biochemical samples (e.g. saliva) for purpose of research

Exclusion criteria

for parents * Smokers having a history of psychiatric/psychological disease or currently on regular psychotropic medications * Smokers using smoking cessation medications or other smoking cessation services or projects

Design outcomes

Primary

MeasureTime frameDescription
Biochemically validated abstinence3-months follow-upsFace-to-face biochemical validation using Alere iScreen OFD saliva cotinine test device

Secondary

MeasureTime frameDescription
Past 7-day point prevalence abstinence (PPA)3-month follow-upPast 7-day PPA will be measured by a self-reported question: Have you ever smoked in the past 7 days?
Smoking reduction3-month follow-up50% or above reduction in cigarette consumption compared with baseline
Use of smoking cessation services3-month follow-upUse of smoking cessation services will be measured by a self-reported question: Have you ever used smoking cessation services in the past 7 days?
Respiratory symptoms3-month follow-upRespiratory symptoms will be measured by a self-reported question: Have you ever experienced respiratory symptoms in the past 7 days? If yes, please list.
Biochemically validated abstinence6-month follow-upFace-to-face biochemical validation using Alere iScreen OFD saliva cotinine test device
Self-reported life quality3-month follow-upQuality of life will be measured by the WHOQoL scale. The total score ranges 0 to 100, with higher scores indicates better quality of life.
Self-reported secondhand exposure3-month follow-upSelf-reported secondhand exposure by children in the past 7 days (yes/no). If yes, we will ask where you are exposed to secondhand smoke and when you are exposed to secondhand smoke.
Self-reported thirdhand exposure3-month follow-upSelf-reported thirdhand exposure by children in the past 7 days (yes/no). If yes, we will ask where you are exposed to thirdhand smoke and when you are exposed to thirdhand smoke.
Perceived family well-being3-month follow-upPerceived family well-being will be measured by the Family Apgar Scale. The total scale ranges from 0 to 10, with the higher score indicating a healthier family function.

Countries

Hong Kong

Contacts

Primary ContactShengzhi Zhao, PhD
lubabezz@connect.hku.hk+852 6561 4500
Backup ContactMengyao Li, MPhil
lmy0814@connect.hku.hk+852 6851 8462

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026